@article{63f152e919a649ab819fa24a9b995440,
title = "New approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies",
abstract = "Non-motor symptoms (NMSs) are highly prevalent throughout the course of Parkinson's disease (PD). Pain, autonomic dysfunction and sleep disturbances remain at the forefront of the most common NMSs; their treatment is challenging and their effect on the quality of life of both patients and caregivers detrimental. Yet, the landscape of clinical trials in PD is still dominated by therapeutic strategies seeking to ameliorate motor symptoms; subsequently, effective strategies to successfully treat NMSs remain a huge unmet need. Wider awareness among industry and researchers is thus essential to give rise to development and delivery of high-quality, large-scale clinical trials in enriched populations of patients with PD-related pain, autonomic dysfunction and sleep. In this review, we discuss recent developments in the field of pharmacological treatment strategies designed or re-purposed to target three key NMSs: pain, autonomic dysfunction and sleep disturbances. We focus on emerging evidence from recent clinical trials and outline some exciting and intriguing findings that call for further investigations.",
author = "Katarina Rukavina and Lucia Batzu and Valentina Leta and Chaudhuri, {K Ray}",
note = "Funding Information: KR is supported by NIHR BRC and Parkinson's UK and has received fees from Valid Insight, Profile Pharma and Britannia. LB has nothing to disclose. VL has received grants from NIHR BRC, Parkinson's UK, a travel and congress grant from Bial UK Ltd, speaker-related activities fees from Britannia pharmaceuticals, Bial UK, and consultancy fees from Invisio Pharmaceuticals, outside the submitted work. KRC. has acted on advisory board for AbbVie, UCB, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Therevance, Scion and Britannia, and has received honoraria for lectures from AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim, and grants (Investigator Initiated) from Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial, Aacdemic grants: EU, IMI EU, Horizon 2020, Parkinson's UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, Welcome Trust.This manuscript presents independent research funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Funding Information: This manuscript presents independent research funded by the National Institute for Health Research ( NIHR ) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2022",
month = may,
day = "1",
doi = "10.1016/j.neuropharm.2022.108959",
language = "English",
volume = "208",
pages = "108959",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
}